Last reviewed · How we verify
AUR103 Calcium
At a glance
| Generic name | AUR103 Calcium |
|---|---|
| Also known as | Trastuzumab, Capecitabine, AUR 103 Calcium |
| Sponsor | Aurigene Discovery Technologies Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE1, PHASE2)
- A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AUR103 Calcium CI brief — competitive landscape report
- AUR103 Calcium updates RSS · CI watch RSS
- Aurigene Discovery Technologies Limited portfolio CI